SRC and breast carcinoma: Overall, this study showed that DEP-1, though known for its tumor suppressor role, functions via the Src/Cortactin pathway to enhance metastatic properties in aggressive breast cancer cell types and is linked to poorer prognosis in patients (Table 2).